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Drug resistanceRNAi loss-of-function screens, which have proven effec-
tive to identify genes functionally responsible for cel-
lular phenotypes, can be designed to use different
genetic backgrounds or altered environmental condi-
tions to elucidate genetic dependencies. These sorts of
screening approaches can be exploited to identify
genetic targets that minimize resistance to approved
drugs, and provide a basis on which to develop new
targeted therapies and predict the secondary targets
for combinatorial treatments. Four types of pooled
short hairpin RNA (shRNA) screens, in particular, have
been used to look for genetic targets that work together
with known drugs or other anticancer targets, either in
an additive or synergistic fashion. Each method pro-
duces results that provide a useful but limited picture
of the genetic elements driving oncogenesis.
Introduction
In the last 10–15 years, molecular classification of cancers
has evolved to the point that it is replacing traditional
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paradigm for developing new diagnoses and treatments. This
molecular perspective has provided significant insights into
carcinogenesis that have led to novel therapeutic approaches.
However, although there have been major advances in mole-
cular analysis over the past 20 years, our understanding of
cancer genetics remains very rudimentary.
Since Golub et al. [1] first proposed classifying cancers using
gene expression data, most oncological molecular character-
ization has been based on transcriptome profiling and DNA
sequencing [2–4]. Although these analyses have been very
useful in targeted drug development for a number of cancers,
these techniques really only allow the elucidation of genetic
characteristics that correlate rather than show a causal con-
nection with oncogenesis. With these techniques, it is not
possible to separate the genetic elements driving an effect
from those that have been changed as a response to the effect
(i.e. the genetic ‘passengers’).
There are two molecular technologies, however, that do
actually disrupt gene functions, and so, reveal the genetic
factors that produce a specific phenotype. Both gene knock-
out and RNA interference technologies provide causal gene-
phenotype data. A major problem, however, with both of
these approaches, is that most phenotypes do not result fromhttp://dx.doi.org/10.1016/j.ddtec.2013.12.002  11ense.
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genetic networks are ‘wired’ impedes understanding of the
genetics of most heritable traits [6]. As a result, knockout or
knockdown of a single essential gene or pathway only pro-
vides limited information about the genetic network inter-
actions producing a phenotype. Further, cancer cells, almost
by definition, are characterized by pathway rewiring, short
circuits, and other signal transduction anomalies as a result of
genetic lesions [7], and the high level of adaptation and
heterogeneity of tumor cells endow them with a remarkable
ability to work around therapeutic challenges [8]. Thus, inhi-
bition of a single essential target or pathway will often not
produce sustained therapeutic effects, and combination thera-
pies will likely be the required treatment for most cancers.
In an attempt to expand the repertoire of combinatorial
treatments, groups have run many screens to identify the
effect of drug pairs on different types of cancer cells [9,10].
However, although some effective combinations have been
found, for example, poly(ADP) ribose polymerase inhibitors
(PARP) in combination with BRCA-positive breast cancer
treatments [11], success with this approach has been limited.
To expand the universe of potential combinations requires a
better understanding of the genetic interactions present in
oncogenic cells. As a result, there is considerable interest in
unbiased approaches to uncover synthetic lethal interac-
tions. Broad-based RNAi screening, with its ability to assay
thousands of genes simultaneously to identify the small
fraction driving a specific response, provides a scalable
approach to screen for functionally critical genes across a
range of cell types [12–14]. Further, since RNA interference
inhibits the expression of, and hence, the function of a gene,
its effect models, to some extent, that of a drug inhibiting the
function of a specific gene product (protein). As a result, this
technique offers an apt approach to screen for synthetic
lethal interactions.
It is relatively straightforward to screen all 20,000 human
protein-coding genes using RNAi to find those that are essen-
tial in a particular cell system as genome-scale screening
studies like Sims et al. [15] and Marcotte et al. [16] have
shown. However, a dropout viability screen of a cell line only
uncovers the most obviously essential genes that by them-
selves produce a lethal phenotype when disrupted. Unravel-
ing more complex genetic interactions that generate the bulk
of cancers requires multiple screens in various cell models
and the integration of these results with other molecular
data, such as two-hybrid maps and transcriptome profiles.
The particular challenge in identifying synthetic lethal inter-
actions is their combinatorial nature. Synthetic phenotypes
do not manifest unless multiple genes are simultaneously
disrupted and, just testing all paired combinations of 20,000
genes, for example, produces 400 million assay combinations
– and most traits likely involve the interaction of more than
just two genetic elements. To make meaningful inroads into12 www.drugdiscoverytoday.comsuch a large assay space requires creative and shrewd use of
the limited experimental tools available, and pooled shRNA
screening is a pivotal tool in the toolbox.
Screening strategies to uncover synthetic interactions
using pooled shRNA libraries
Several curated collections are available to facilitate running
RNAi screens in arrayed formats with each well containing
individual or small pools of siRNA molecules or shRNA con-
structs. One advantage of this approach is that the oligonu-
cleotides or expression constructs in this format can be
used in combination with other biological assays, including
high-content screening. For example, Laufer et al. [17] used
combinatorial RNAi screens in an arrayed format to look at
the interaction of epigenetic regulatory genes on several
morphological phenotypes of colon cancer cell, such as
eccentricity, nuclear area, and mitotic index. However, given
the expansive assay domain that needs to be mapped to
identify synthetic lethal interactions, single assay screens
using complex pools of shRNA expression constructs offer
a more practical approach.
Complex pooled shRNA libraries are typically constructed
in a lentiviral vector system so that large numbers of shRNA
expression constructs can be easily introduced into cells
efficiently. With a pooled-screen approach, a single library
that encodes the whole set of packaged viral shRNA con-
structs is introduced into a population of cells via a single
large-scale transduction (Fig. 1). The shRNA expression cas-
settes integrate into the genomic DNA of transduced cells and
generate stable gene-knockdown cells. The library-trans-
duced cells are then incubated for a period of time to allow
the shRNA to express and the phenotype to manifest. When
running dropout viability assays to identify cytotoxic
shRNAs, we typically maintain transduced cells for 6–12
doublings. After growth, surviving cells are harvested, and
the relative quantity of each shRNA construct is determined
by high-throughput sequencing of the expression cassettes
recovered by PCR from the cells’ isolated genomic DNA. The
relative quantities of each shRNA in the cell population after
several doublings can be compared with the relative quan-
tities of each shRNA in the initial library to identify which
shRNAs are underrepresented in the cells after several dou-
blings. The ‘depleted’ shRNAs either killed or inhibited
growth of the cells, presumably because they interfere with
genes required for survival or robust cell growth and prolif-
eration. One important advantage of the RNAi pooled-screen-
ing technique is that it does not require major automation
infrastructure or special liquid handling.
Pooled shRNA dropout screens have been successfully used
by a number of groups for several years to identify essential
genes [18,19]. Successful application of this technique
simply requires the use of the well characterized libraries
and careful screening methodology. Some of the initial
Vol. 11, 2014 Drug Discovery Today: Technologies | Drug resistance
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Figure 1. Dropout viability screening process. An overview of the dropout viability screening process to find genes required by cells growing in the
presence of a drug or other factor. The left panel screen identifies genes generally required by the cell line for proliferation. In the right panel, screen cells
are treated with a low dose of the compound after transduction. This screen finds both generally essential genes and genes essential for growth in the
presence of the drug. Hits identified specifically in the right panel screen with the drug indicate genes whose expression confers some resistance to the drug
since loss of the gene’s function enhance sensitivity.libraries were developed about 10 years ago, and a number of
advancements have been made since then. For example, to
facilitate accurate measurement of the relative amount of
each shRNA in a population, our libraries include short
unique sequences optimized for high-throughput analysis
(i.e. barcodes). PCR amplification followed by high-through-
put sequencing of these optimized barcodes is more robust
and less variable than direct amplification and sequencing of
the hairpin sequence of the shRNA (data not shown). Also,
use of libraries optimized for high-throughput sequencing
ensures all shRNAs are represented in comparable numbers to
accurately assess depletion or enrichment during a screen.
This sort of analysis of library quality is critical since the most
important factor influencing screening reproducibility is the
degree to which the shRNAs in the population of transduced
cells at the start of a screen reflects the full complement of
shRNAs present in the original library. A sufficient number of
cells need to integrate each construct in the library during the
initial transduction, and the progeny of these cells must be
maintained at high enough levels through screening to ensure
that changes in the abundance of cells expressing a given
shRNA are due to the effect of that shRNA on cell proliferation,
and not simple stochastic variation. If well-characterizedlibraries are not used and these parameters defining the size
the screen relative to the shRNA frequency and distribution in
the library not observed, then it is difficult to separate true hits
from random variation in the results. In such cases, simple
noise can easily be mistaken for an important result, as was the
case where STK33 was identified as essential in KRAS-depen-
dent cancer cells [20]. This work was later showed to be a result
of some procedural problems with the screen [21,22].
Below we provide some examples of four general
approaches that use complex pooled shRNA libraries to iden-
tify different sorts of synthetic lethal interactions:
Dropout viability screens with a compound
Perhaps the most direct approach to identify essential gene
targets in cells resistant to a drug is simply to run a dropout
viability screen in the presence of the drug. This approach
uncovers genes that, when inhibited, sensitize cells to a drug’s
lethal effect. This sort of screen involves simply treating cells
with a minimal dose of the drug, then running a dropout
viability screen to identify genes whose loss of function is
lethal. ‘Hits’ (i.e. the target genes of depleted shRNA) from the
screen run in the presence of the compound are, of course,
then compared with a similar set of gene hits from a controlwww.drugdiscoverytoday.com 13
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enables identification of the interference targets that are
critical for cell viability only in the presence of the drug –
the ones that are synthetically lethal with the compound.
A study by researchers at the Netherlands Cancer Institute
and University of Torino used a dropout viability screen
with a pooled shRNA library targeting 535 kinase genes to
ascertain why melanoma cancer cells harboring the BRAF
(V600E) mutation are sensitive to PLX4032 (vemurafenib)
whereas prostate cancers with the same mutation are not
[23]. Colorectal cells containing the BRAF mutation and
resistant to PLX4032 were infected with the pooled library
and cultured in the absence or presence of the compound.
Three of the shRNA that were depleted in this screen tar-
geted EGFR, and it was confirmed that suppression of EGFR
only in the presence of PLX4032 markedly inhibited growth
of these cells. The cells also responded strongly to combina-
tion treatment of PLX4032 with EGFR-targeting antibodies
(either cetuximab or gefitinib). Subsequent follow up work
showed that BRAF inhibition activates EGFR. The fact that
most melanoma lines, and colorectal cell lines sensitive to
PLX3032, express very low levels of BRAF seems to explain
the difference in sensitivity of these two cancers to this
compound.
A recent publication from the German Cancer Research
Center (DKFZ) made use of this screening method to identify
targets that act synthetically with the approved drug gemci-
tabine [24]. The researchers looked for genes that support
pancreatic cancer cell resistance to gemcitabine by running
dropout viability RNAi screens in the presence of the drug
using Cellecta’s DECIPHER shRNA libraries targeting 10,000
human genes. A pancreatic cancer cell line was transduced
with the libraries, then treated with low levels of gemcitabine
– or not, for the control – and then allowed to grow for an
extended period. The authors identified about 70 genes with
synthetic lethal effects in combination with gemcitabine.
Highly represented in the hits from the gemcitabine screen
were genes involved in DNA damage response and repair,
which was expected since gemcitabine is a DNA damaging
agent. The study authors focused specifically on genes iden-
tified in the screen that were upstream of checkpoint kinase 1
(CHK1) of the ATR/CHK1 pathway, and confirmed RAD17,
HUS1, and WEE1 with three independent shRNA constructs.
Further analysis revealed that these three genes appear to
increase gemcitabine lethality by forcing treated cells with
damaged DNA to enter mitosis.
Other examples of this sort of dropout screen to identify
sensitizers in cells resistant to a drug include a screen by
Qin et al. [25] to find synthetic lethal genes that work in
conjunction with the anti-inflammatory/antitumor agent
CDDO-Me, and Mills and colleagues’ study [26] that identi-
fied lethal sensitivity of ABT-737-treated lymphoma cells to
DHX9 knockdown.14 www.drugdiscoverytoday.comIt is also possible to use a similar, but ‘reverse,’ version of
this screening strategy to identify genes that are required for
the cell to maintain sensitivity to a drug, sometimes called
synthetic dosage lethality [27]. To find genes whose expres-
sion (rather than disruption) enhances sensitivity to a drug or
other factor when a high dose of the drug, or other death-
inducing factor, is used to kill the bulk of the cells, then
the analysis is done with the few that survive this selection.
RNAi screening to identify genes involved in an apoptotic
response, for example by Dompe et al. [28], is one example of
this sort of positive-selection screen. Similar sorts of synthetic
dosage effects can be found for drugs, although it is less
common than lethality caused by a simple disruption of
two (or more) targets. This is probably because most mole-
cularly targeted anticancer drugs work by disruption of a
signaling pathway. However, there are genetic mechanisms
that can ameliorate the effects produced by inhibiting an
essential pathway. For example, in the lymphoma screen
with ABT-737 discussed in the previous section, cells over-
expressing myeloid leukemia cell differentiation protein
Mcl-1 display resistance to the drug. In fact, this synthetic
dosage lethal mode of resistance needed to be incorporated
into the cell model through constitutive expression of Mcl-1
to enable effective selection of synthetic lethality effects in
this study.
Dropout viability screens in defined genetic backgrounds
Instead of looking for synthetic lethal gene interactions
directly with a drug, an alternative is to look for genes that
are only essential in cells with specific genotypes or particular
genetic lesions. This sort of screen reflects the strict definition
of synthetic lethality – two or more viable non-allelic genetic
variants are lethal when present together in the same cell.
Actually, most RNAi dropout viability screens fall into this
category. For example, one of the early dropout screens by
Schlabach et al. [29] using a murine stem cell virus library of
8203 shRNAs targeting 2924 genes found essential genes
specific to two colon cancer cells they screened, but the hits
did not show up in parallel breast cancer or mammary cell
screens. Around the same time, in a more narrowly defined
synthetic lethal screen targeting only 88 kinases, Bommi-
Reddy et al. [30] found that three kinases – CDK6, MET, and
MAP2K1 – were lethal in renal carcinoma cells negative for
the von Hippel-Lindal (VHL-) tumor suppressor activity, but
not in an isogenic line without the VHL mutation.
Also, more recent studies have profiled panels of cells to
identify vulnerabilities in cancers associated with specific
tissues. For example, Cheung et al. [31] screened more than
11,000 genes in 102 cancer cell lines and identified a number
of lineage-specific dependencies, then cross referenced the
results with transcription profiling data of tumors. They
found 5 genes specifically essential in ovarian cancer cells
and overexpressed in a high percentage of ovarian tumors.
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Figure 2. Dropout viability screen to identify prostate-specific essential genes. Panel A is a ‘heat map’ that depicts levels of significant depletion for 7000
shRNA in a screen targeting 1200 prostate-specific genes in 5 prostate and 3 other cell lines. Red or orange indicates no significant change in the shRNAs
targeting the gene over time, whereas blue indicates genes with the most significantly depleted shRNAs. Panel B: Confirmation result for 17 genes identified in
the screen that had two or more shRNA targeting them significantly depleted specifically in prostate cells, as well as two controls that were not depleted in any
cells. For confirmation, two shRNAs targeting each selected gene were synthesized, cloned, and transduced into all cell lines. The table compares the anticipated
effect of the shRNAs on the cells based on the screening data (predicted) with the actual effect seen when the shRNAs were expressed in the cells.One of these genes, PAX8, plays a critical role in female
genital track development and induces apoptotic cell death
when inhibited. Brough et al. [32] profiled 30 common breast
cancer cell lines using arrayed siRNA screening and discov-
ered that cells with mutated PTEN were sensitive to inhibition
of TTK protein kinase which is involved in mitotic spindle
assembly. Also, estrogen positive tumor lines were sensitive
to ADCK2 knockdown. We also have run a tissue-specific
dropout viability study in-house to identify genes specifically
lethal to androgen-receptor positive prostate cancer cells
using a small shRNA library targeting 1200 prostate-cancer
associated human genes. This small screen identified cyclin
D1 as specifically essential in these cells but not in androgen
receptor negative variants (Fig. 2) [33].
As a well-known oncogene, several groups have tried to
identify synthetic lethal interactors with KRAS. As mentioned
above, it was one of these early screens, by Scholl et al., which
led to STK33 putative synthetic interaction with KRAS that
attracted a lot of attention but later turned out to be a false
positive. However, a later study by Vicent et al. [34] did
identify several KRAS-specific lethal genes in lung carcinoma.
The researchers screened two mouse KRAS-driven non-small
lung cancer cell lines with a pooled lentiviral library consist-
ing of 631 shRNA against 162 targets that had been impli-
cated in the KRAS genetic network based on previous broader
RNAi screens and gene expression analyses. Interestingly, for
this analysis, the authors ran the screen using in vivo xeno-
graft implantations of the transduced cells, as well as the
standard in vitro culture. Of the 23 genes with at least two
depleted shRNAs, three – Rac1, Phb2, and Wt1 – were foundto be specifically lethal only in cells where KRAS-signaling is
active. Rac1 had been previously linked to KRAS signaling
and Phb2 is a known chaperonin protein active during apop-
tosis. However, the function of Wt1, which appeared to have
some transcriptional activation activity, was unknown.
Vicent et al. went on to demonstrate that WT1 interference
leads to growth arrest and senescence in the presence of
oncogenic KRAS.
Dropout viability screens in defined phenotypic models
Rather than looking for genes that produce specific lethality
in cells with particular genetics as described above, a similar
approach can be used to discover genes specifically lethal to
cells generally displaying a common phenotype.
Lamy et al. [35] recently published a study that used this
approach to identify a dependence of multiple myeloma cells
on caspase-10. Myeloma cells are genetically heterogeneous.
Despite this, genetically consistent dependencies across all
myeloma cells have been found. For example, myelomas
appear to require transcription factor IRF4 expression [36].
Based on this, the researchers sought out other essential drivers
specific to myeloma cells. Using an inducible retroviral-based
shRNA library targeting 2500 human genes, the authors
screened three myeloma lines and found that shRNA targeting
caspase-10 was depleted significantly compared with screens
in four other lymphoma lines. They pursued these results and
determined that caspase-10 is a downstream effector of IRF4
and blocks autophagy-dependent death of myeloma cells.
This phenotypic-centric approach can also be used to
screen for genes required for drug resistance. As outlinedwww.drugdiscoverytoday.com 15
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enhances sensitivity to the drug is to run a dropout screen in
the presence of the drug. However, an alternative approach is
to look for any gene specifically essential for the viability of
cells displaying the drug resistant phenotype. The premise, of
course, is that cells that have developed resistance to the drug
have rewired their pathways in some way to minimize the
disruption caused by the compound. Dropout screens to find
genes specifically essential in cells with the resistant pheno-
type, then, can help elucidate the mechanism of resistance
and, further, may provide novel drug targets that can be used
to prevent the development of resistance in the presence of
the drug. We have run this sort of screen to look for required
pathways in ovarian cancer cells resistant to cisplatin as
shown in Fig. 3.
Combinatorial gene-by-gene knockdown analysis
A very direct RNAi-based approach to find lethal gene com-
binations is simply to look for lethality when two or more
genes are knocked down in a single cell. One approach to doA2780
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16 www.drugdiscoverytoday.comthis is to run standard dropout screens using a stable knock-
down cell line in the same way one would run screens using
cells with a knocked out gene. However, this approach
becomes more difficult when the object is to look for a
broader range of lethal combinations, say, for example, if
one wanted to find all synthetically interacting gene pairs in
two cellular pathways.
To map out synthetic lethal interactions between large sets
of genes requires a way of assessing, on a paired gene-by-gene
basis, the effect of knocking down each two-gene combina-
tion at the same time. For this sort of analysis, we have
developed a vector that expresses two shRNAs simultaneously
and devised an approach to construct a complete shRNA
library with a defined set of hairpins expressed from each
position of this vector. The approach creates a library wherein
each shRNA expressed in one position is individually paired
with all the shRNAs in the second position, allowing all
combinations of the two sets of shRNAs to be assayed in a
single screen. We tested this combinatorial library using a
dual shRNA expression vector with a set of four shRNAsREACTOME: CELL CYCLE MITOTIC OVERLAP
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 ovarian cancer cells. We screened ovarian cancer cell line A2780 that is
ECIPHER library that targets 5000 genes with 27,500 shRNA expression
mpared to identify viability gene targets unique to A2780R cells. About 200
endent shRNAs. Preliminary pathway analysis revealed that these hits were
 checkpoints, DNA mismatch and nucleotide excision repair, as may have
etrix U133 + 2 arrays to identify up- and down-regulated genes in cisplatin
cripts, of which about 50% overlapped with the RNAi screen.
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Table 1. A comparison of RNAi dropout viability screening methods
Screening method Results yield. . . Results predict. . . Results may show. . .
Screen with compound Genes involved in resistance
to drug effects
Genes that can be targeted to enhance
sensitivity to known drug
Drug mechanism of action and/or
compensatory pathways for resistance
Screen in defined
genetic background
Genes that are synthetic lethal
with defined oncogenic lesions
Genetic vulnerabilities in cancers
with specific genetic lesions
Genetic ‘addictions’ produced by
various genetic lesions
Screen in defined
phenotypic models
Genes essential in cells with
particular traits
Possible phenotypic markers associated
with genetic sensitivities
Genetic factors responsible
for phenotypes
Combinatorial
RNAi screen
Essential paired gene combinations
with additive or synergistic interactions
Most lethal gene combinations to
target for therapeutic intervention
Unexpected and novel
genetic interactionstargeting each of 40 DNA damage and repair genes. The total
library contained over 25,000 constructs since each construct
expressed a different paired combination of the 160 shRNAs.
After running a standard dropout viability screen, dual
shRNA expressing constructs targeting 13 pairs of genes were
significantly depleted in hTERT-immortalized human mam-
mary epithelial cells (HMEC), including the PARP1/BRCA1
combination that has been previously reported by Ashworth
[11].
While it is not feasible to run this sort of combinatorial
pair-wise RNAi screen exhaustively on the whole genome in a
single screen due to the number of combinations, a pooled
screen with a dual shRNA expression construct is really the
only practical option for this sort of analysis with even a
moderately sized set of shRNAs. A pair-wise combinatorial
approach using an arrayed format to screen two targets per
well rapidly becomes very costly and resource prohibitive.
However, a reasonable set of genes can be selected for a
combinatorial pooled screening using any number of tech-
niques. For example, Bassik et al. [37] used this approach to
characterize the interactions in a set of genes involved with
ricin sensitivity. In this study, the authors used a dual shRNA
expression library for a follow up screen designed around the
positives identified in a broad-based standard shRNA loss-of-
function screen. Also, this sort of combinatorial screen using
a pooled library can be run in conjunction with one of the
previously mentioned approaches to uncover interacting
genes specific for cells with certain genotypes or phenotypes.
Conclusion
Cancer patients often talk about their ‘battle’ with the dis-
ease, and the metaphor is certainly an apt fit. Cancer treat-
ment can be viewed as an ongoing war against an evolving
population of tumor cells fighting to neutralize the effect of
the latest chemical attack. The disease almost always recovers
from the first attack, and the result leads to an escalating arms
race of therapeutic intervention.
It is clear that in many, if not most, cases eliminating the
resilient carcinogenic invaders will require a combination of
approaches. Determining effective combinations for different
tumors, though, requires a better understanding of the tacticseach employs to overcome therapeutic intervention. What
cellular networks do various cancers rely on for rapid growth,
what pathways can they fall back on in response to a chal-
lenge, how do different cancers suppress normal growth
controls, and what novel genetic vulnerabilities do the cells
expose through this rewiring? It is this knowledge that will
eventually enable us to anticipate and prevent resistance
mechanisms and thwart the tumor adaptations before they
can be established. At present, RNAi screening is one of the
few tools available that uncovers the effective particular
genetic elements responsible for producing and preserving
these oncogenic phenotypes (Table 1).
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